Document Detail

Effectiveness of Pentavalent Rotavirus Vaccine Against Severe Disease.
MedLine Citation:
PMID:  21768317     Owner:  NLM     Status:  Publisher    
Objective: To determine the vaccine effectiveness (VE) of complete and partial vaccination with the pentavalent rotavirus vaccine (RV5) in the prevention of rotavirus acute gastroenteritis (AGE) hospitalizations and emergency department visits during the first 3 rotavirus seasons after vaccine introduction. Methods: Active, prospective population-based surveillance for AGE and acute respiratory infection (ARIs) in inpatient and emergency department settings provided subjects for a case-control evaluation of VE in 3 US counties from January 2006 through June 2009. Children with laboratory-confirmed rotavirus AGE (cases) were matched according to date of birth and onset of illness to 2 sets of controls: children with rotavirus-negative AGE and children with ARI. The main outcome measure was VE with complete (3 doses) or partial (1 or 2 doses) RV5 vaccination. Results: Of age-eligible children enrolled, 18% of cases, 54% of AGE controls, and 54% of ARI controls received ≥1 dose of RV5. The VE of RV5 for 1, 2, and 3 doses against all rotavirus genotypes with the use of rotavirus-negative AGE controls was 74% (95% confidence interval [CI]: 37%-90%), 88% (95% CI: 66%-96%), and 87% (95% CI: 71%-94%), respectively, and with the use of ARI controls was 73% (95% CI: 43%-88%), 88% (95% CI: 68%-95%), and 85% (95% CI: 72%-91%), respectively. The overall VE estimates were comparable during the first and second years of life and against AGE caused by different rotavirus strains. Conclusion: RV5 was highly effective in preventing severe rotavirus disease, even after a partial series, with protection persisting throughout the second year of life.
Mary Allen Staat; Daniel C Payne; Stephanie Donauer; Geoffrey A Weinberg; Kathryn M Edwards; Peter G Szilagyi; Marie R Griffin; Caroline B Hall; Aaron T Curns; Jon R Gentsch; Shelia Salisbury; Gerry Fairbrother; Umesh D Parashar;
Related Documents :
11353527 - Synthesis and biological evaluation of an anticancer vaccine containing the c-glycoside...
17635157 - Cell-penetrating peptide-morpholino conjugates alter pre-mrna splicing of dmd (duchenne...
7551027 - A linear b-cell epitope on the class 3 outer-membrane protein of neisseria meningitidis...
16096927 - Hla-binding peptides as a therapeutic approach for chronic hiv infection.
16504347 - A nematode allergen elicits protection against challenge infection under specific condi...
12220157 - Porcine zona pellucida (pzp) immunocontraception of wild horses (equus caballus) in nev...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-18
Journal Detail:
Title:  Pediatrics     Volume:  -     ISSN:  1098-4275     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-7-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Pediatrics and.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Airway Expression of the Epithelial Sodium Channel {alpha}-Subunit Correlates With Cortisol in Term ...
Next Document:  Efficacy of neonatal release of ankyloglossia: a randomized trial.